Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are MiNK Therapeutics Insiders Buying or Selling?
MiNK Therapeutics (INKT) has had no reported insider transactions in the past 90 days. The most recent was Barbara Ryan, who sold 1,000 shares at $12.80 on June 4, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the INKT AI Score. For government officials trading this stock, see INKT congressional trading.
Who’s Trading MiNK Therapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Barbara Ryan | Sold $39,000 | 7 | Jun 4, 2026 |
Recent MiNK Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Barbara Ryan | Jun 4, 2026 | Sell | 1,000 | $12.8 | $13,000 |
| Barbara Ryan | Jun 4, 2026 | Sell | 500 | $12.68 | $6,300 |
| Barbara Ryan | Mar 10, 2026 | Sell | 500 | $15.3 | $7,700 |
| Barbara Ryan | Mar 10, 2026 | Sell | 300 | $15.28 | $4,600 |
| Barbara Ryan | Mar 9, 2026 | Sell | 200 | $10.17 | $2,000 |
| Barbara Ryan | Mar 2, 2026 | Sell | 100 | $10.83 | $1,100 |
| Barbara Ryan | Feb 27, 2026 | Sell | 400 | $10.86 | $4,300 |
Frequently Asked Questions: MiNK Therapeutics Insider Trading
MiNK Therapeutics insiders have not reported any transactions in the past 90 days.
The most recent sale was by Barbara Ryan who sold 1,000 shares on June 4, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Ryan Barbara has sold the most INKT stock in the last 2 years, with a total value of $39,000.
The total value of insider transactions for MiNK Therapeutics in the last 2 years is negative, amounting to -$39,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
